Academy of Physicians
in Clinical Research

Academy of Physicians
in Clinical Research




News from SCRIP

APCR Members can get a free trial to SCRIP and a discount on a SCRIP subscription by contacting John Lezcano from SCRIP directly at the information below. 

John Lezcano
Corporate Account Manager

Pharma intelligence | informa
T: (212) 652-2678
M: (631) 807-4971
John.lezcano@informa.com
pharmaintelligence.informa.com

Japan Phase III Failure To End Mono Opdivo Hopes In Ovarian Cancer?

Mon, 01/27/2020 - 6:46pm

While disappointing result will probably put an end to single-drug plans in ovarian cancer, the blockbuster anti-PD-1 immunotherapy remains in...

      Related Stories 

The ICER Process: Allergan Engagement Improves Cost Effectiveness Rating For Ubrelvy

Mon, 01/27/2020 - 11:52am

ICER president Steve Pearson is ‘cautiously optimistic’ that net pricing for acute migraine treatments will align with benefits once discounts...

      Related Stories 

Novartis Pharma President Marie-France Tschudin On Inclisiran, Launches And More

Mon, 01/27/2020 - 10:22am

Tschudin talked to Scrip about taking over as Novartis Pharmaceuticals president, why inclisiran is different from marketed PCSK9 inhibitors and...

       

AZ Closer To Second Enhertu OK After Gastric Cancer Success

Mon, 01/27/2020 - 7:37am

The Daiichi Sankyo-partnered antibody drug conjugate has just been approved for breast cancer and AstraZeneca's oncology R&D chief tells Scrip...

      Related Stories 

Stockwatch: Earnings Season Catches An Early Cold As Coronavirus Sweeps In

Mon, 01/27/2020 - 4:55am

As industry bellwether J&J kicked-off 2019 fourth-quarter and full-year earnings season for life sciences companies, its financial results left investors...

      Related Stories 

Moderna, Inovio Coronavirus Vaccine Candidates Fast-Tracked By International Coalition

Mon, 01/27/2020 - 12:19am

The Coalition for Epidemic Preparedness Innovations adds new deal with mRNA specialist Moderna for rapid development of coronavirus vaccine.

      Related Stories 

Rising Costs, Price Pressure Usher In Uncertain Year Of The Rat In China

Sun, 01/26/2020 - 8:59pm

Once the world's factory, China has seen costs inch up while drug prices are being cut deeply by centralized procurement...

      Related Stories 

Biocon-Mylan's Plans For Broader US Fulphila Access, Glargine On Track

Sun, 01/26/2020 - 8:17pm

Biocon-Mylan press ahead with plans to broaden patient access in the US to biosimilar pegfilgrastim and are enthused with the...

      Related Stories 

JT Gains World-First Topical JAK Inhibitor Approval

Sun, 01/26/2020 - 7:45pm

Latest new drug approvals in Japan include the first anywhere for a topical JAK inhibitor and also a marketing clearance...

      Related Stories 

Epizyme’s Tazverik Gets To Market In Rare Sarcoma, Paving Way To Bigger Indications

Fri, 01/24/2020 - 12:21pm

Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger...

      Related Stories 

Finance Watch: 2019 Ended With Near-Record VC Financings, But Some Slowing Expected In 2020

Fri, 01/24/2020 - 11:15am

Private Company Edition: VC deals fell short of the record-breaking level seen in 2018 and financings may slow a bit...

      Related Stories 

New CEO Brett Monia Takes The Lead As Ionis Prioritizes Non-Partnered Programs

Fri, 01/24/2020 - 8:24am

Monia told Scrip at the J.P. Morgan Healthcare Conference that the company will be more selective about partnerships going forward...

      Related Stories 

After Real-World Data Row, AZ Looks To NHS England For Tagrisso Deal

Fri, 01/24/2020 - 7:30am

Tagrisso has become AstraZeneca’s oncology flagship product, but cannot secure frontline use in England.

      Related Stories 

J&J's Stelara Gets Europe OK For Pediatric Psoriasis

Fri, 01/24/2020 - 6:53am

The European Commission has backed J&J's blockbuster to treat children with psoriasis but the drug has fallen foul of NICE...

      Related Stories 

Tecentriq Disappoints In Post-Surgery Bladder Cancer

Fri, 01/24/2020 - 12:47am

Failure is a knock-back for the blockbuster product, but Tecentriq has many more opportunities for trial success in 2020.

      Related Stories 

Kissei Discussing Rovatirelin Path After Mixed Phase III Results

Thu, 01/23/2020 - 7:51pm

Japanese firm in discussions with regulator as high-need novel therapy for spinocerebellar degeneration misses endpoint but shows promise in pooled...

      Related Stories 

Decade In Review: C-Suite Shifts At Family-Owned Indian Firms

Thu, 01/23/2020 - 3:12pm

Scrip traces some of the prominent changes in the corner office at front-line, family-owned Indian firms Cipla and Dr Reddy’s...

      Related Stories 

Pages